Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG.
Bartsch R, et al. Among authors: zielinski cc.
Eur J Cancer. 2012 Sep;48(13):1932-8. doi: 10.1016/j.ejca.2012.03.002. Epub 2012 Mar 27.
Eur J Cancer. 2012.
PMID: 22459763
Clinical Trial.